Crohn's disease in a southern European country: Montreal classification and clinical activity

Detalhes bibliográficos
Autor(a) principal: Magro, F
Data de Publicação: 2010
Outros Autores: Portela, F, Lago, P, Ramos de Deus, J, Vieira, A, Peixe, P, Cremers, I, Cotter, J, Cravo, M, Tavares, L, Reis, J, Gonçalves, R, Lopes, H, Caldeira, P, Ministro, P, Carvalho, L, Azevedo, L, Costa-Pereira, A
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.4/1362
Resumo: BACKGROUND: Given the heterogeneous nature of Crohn's disease (CD), our aim was to apply the Montreal Classification to a large cohort of Portuguese patients with CD in order to identify potential predictive regarding the need for medical and/or surgical treatment. METHODS: A cross-sectional study was used based on data from an on-line registry of patients with CD. RESULTS: Of the 1692 patients with 5 or more years of disease, 747 (44%) were male and 945 (56%) female. On multivariate analysis the A2 group was an independent risk factor of the need for steroids (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.1-2.3) and the A1 and A2 groups for immunosuppressants (OR 2.2; CI 1.2-3.8; OR 1.4; CI 1.0-2.0, respectively). An L3+L3(4) and L(4) location were risk factors for immunosuppression (OR 1.9; CI 1.5-2.4), whereas an L1 location was significantly associated with the need for abdominal surgery (P < 0.001). After 20 years of disease, less than 10% of patients persisted without steroids, immunosuppression, or surgery. The Montreal Classification allowed us to identify different groups of disease severity: A1 were more immunosuppressed without surgery, most of A2 patients were submitted to surgery, and 52% of L1+L1(4) patients were operated without immunosuppressants. CONCLUSIONS: Stratifying patients according to the Montreal Classification may prove useful in identifying different phenotypes with different therapies and severity. Most of our patients have severe disease.
id RCAP_b51f0d0ef46e249cf71ed389396e2e1e
oai_identifier_str oai:rihuc.huc.min-saude.pt:10400.4/1362
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Crohn's disease in a southern European country: Montreal classification and clinical activityDoença de CrohnPortugalBACKGROUND: Given the heterogeneous nature of Crohn's disease (CD), our aim was to apply the Montreal Classification to a large cohort of Portuguese patients with CD in order to identify potential predictive regarding the need for medical and/or surgical treatment. METHODS: A cross-sectional study was used based on data from an on-line registry of patients with CD. RESULTS: Of the 1692 patients with 5 or more years of disease, 747 (44%) were male and 945 (56%) female. On multivariate analysis the A2 group was an independent risk factor of the need for steroids (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.1-2.3) and the A1 and A2 groups for immunosuppressants (OR 2.2; CI 1.2-3.8; OR 1.4; CI 1.0-2.0, respectively). An L3+L3(4) and L(4) location were risk factors for immunosuppression (OR 1.9; CI 1.5-2.4), whereas an L1 location was significantly associated with the need for abdominal surgery (P < 0.001). After 20 years of disease, less than 10% of patients persisted without steroids, immunosuppression, or surgery. The Montreal Classification allowed us to identify different groups of disease severity: A1 were more immunosuppressed without surgery, most of A2 patients were submitted to surgery, and 52% of L1+L1(4) patients were operated without immunosuppressants. CONCLUSIONS: Stratifying patients according to the Montreal Classification may prove useful in identifying different phenotypes with different therapies and severity. Most of our patients have severe disease.WileyRIHUCMagro, FPortela, FLago, PRamos de Deus, JVieira, APeixe, PCremers, ICotter, JCravo, MTavares, LReis, JGonçalves, RLopes, HCaldeira, PMinistro, PCarvalho, LAzevedo, LCosta-Pereira, A2012-04-30T14:14:53Z20102010-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/1362engInflamm Bowel Dis. 2009;15(9):1343-50.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-11T14:22:38Zoai:rihuc.huc.min-saude.pt:10400.4/1362Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:03:53.329951Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Crohn's disease in a southern European country: Montreal classification and clinical activity
title Crohn's disease in a southern European country: Montreal classification and clinical activity
spellingShingle Crohn's disease in a southern European country: Montreal classification and clinical activity
Magro, F
Doença de Crohn
Portugal
title_short Crohn's disease in a southern European country: Montreal classification and clinical activity
title_full Crohn's disease in a southern European country: Montreal classification and clinical activity
title_fullStr Crohn's disease in a southern European country: Montreal classification and clinical activity
title_full_unstemmed Crohn's disease in a southern European country: Montreal classification and clinical activity
title_sort Crohn's disease in a southern European country: Montreal classification and clinical activity
author Magro, F
author_facet Magro, F
Portela, F
Lago, P
Ramos de Deus, J
Vieira, A
Peixe, P
Cremers, I
Cotter, J
Cravo, M
Tavares, L
Reis, J
Gonçalves, R
Lopes, H
Caldeira, P
Ministro, P
Carvalho, L
Azevedo, L
Costa-Pereira, A
author_role author
author2 Portela, F
Lago, P
Ramos de Deus, J
Vieira, A
Peixe, P
Cremers, I
Cotter, J
Cravo, M
Tavares, L
Reis, J
Gonçalves, R
Lopes, H
Caldeira, P
Ministro, P
Carvalho, L
Azevedo, L
Costa-Pereira, A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv RIHUC
dc.contributor.author.fl_str_mv Magro, F
Portela, F
Lago, P
Ramos de Deus, J
Vieira, A
Peixe, P
Cremers, I
Cotter, J
Cravo, M
Tavares, L
Reis, J
Gonçalves, R
Lopes, H
Caldeira, P
Ministro, P
Carvalho, L
Azevedo, L
Costa-Pereira, A
dc.subject.por.fl_str_mv Doença de Crohn
Portugal
topic Doença de Crohn
Portugal
description BACKGROUND: Given the heterogeneous nature of Crohn's disease (CD), our aim was to apply the Montreal Classification to a large cohort of Portuguese patients with CD in order to identify potential predictive regarding the need for medical and/or surgical treatment. METHODS: A cross-sectional study was used based on data from an on-line registry of patients with CD. RESULTS: Of the 1692 patients with 5 or more years of disease, 747 (44%) were male and 945 (56%) female. On multivariate analysis the A2 group was an independent risk factor of the need for steroids (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.1-2.3) and the A1 and A2 groups for immunosuppressants (OR 2.2; CI 1.2-3.8; OR 1.4; CI 1.0-2.0, respectively). An L3+L3(4) and L(4) location were risk factors for immunosuppression (OR 1.9; CI 1.5-2.4), whereas an L1 location was significantly associated with the need for abdominal surgery (P < 0.001). After 20 years of disease, less than 10% of patients persisted without steroids, immunosuppression, or surgery. The Montreal Classification allowed us to identify different groups of disease severity: A1 were more immunosuppressed without surgery, most of A2 patients were submitted to surgery, and 52% of L1+L1(4) patients were operated without immunosuppressants. CONCLUSIONS: Stratifying patients according to the Montreal Classification may prove useful in identifying different phenotypes with different therapies and severity. Most of our patients have severe disease.
publishDate 2010
dc.date.none.fl_str_mv 2010
2010-01-01T00:00:00Z
2012-04-30T14:14:53Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.4/1362
url http://hdl.handle.net/10400.4/1362
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Inflamm Bowel Dis. 2009;15(9):1343-50.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131701627060224